CYTOKINETICS INC

Founded in 1997 and headquartered in South San Francisco, Cytokinetics is a late-stage biopharmaceutical company focused on discovering and developing small molecule drug candidates designed to modulate muscle function and contractility. The company's pipeline targets cardiovascular and neuromuscular conditions through two primary mechanisms: muscle activators and muscle inhibitors. Its most advanced candidate, omecamtiv mecarbil, is a cardiac myosin activator in Phase III trials for heart failure patients. The company is also developing aficamten, a cardiac myosin inhibitor in Phase III trials for hypertrophic cardiomyopathy treatment. Earlier-stage programs include CK-089, a fast skeletal muscle troponin activator in Phase I trials, and CK-586, a cardiac myosin inhibitor in Phase II trials.

The company operates primarily through clinical development and licensing agreements. Cytokinetics has established strategic partnerships to advance its pipeline, including a collaboration with Ji Xing Pharmaceuticals Limited and a license agreement for aficamten's development and commercialization in Japan. The company remains pre-commercial, with revenue generation dependent on the clinical advancement and potential regulatory approval of its drug candidates. Geographic reach extends across the United States as its primary market, with expanding opportunities through international partnerships in markets such as Japan.